Key result
HO-1/CO pathway inhibits antiangiogenic factors sFlt-1 and sEng, emerging as a therapeutic target in preeclampsia.
Why the study?
The role of HO-1 in regulating sFlt-1 and sEng release and its potential protective effect in pregnancy-related conditions like preeclampsia was not established.
Does the HO-1/CO pathway inhibit sFlt-1 and sEng release in the context of pregnancy and preeclampsia?
Does the HO-1/CO pathway inhibit sFlt-1 and sEng release in the context of pregnancy and preeclampsia?
The HO-1/CO pathway inhibits the release of sFlt-1 and sEng, identifying HO-1 as a potential novel therapeutic target for preeclampsia.
HO-1 induction merits exploration as preeclampsia therapy; leaves open translation to clinical pregnancy outcomes.
The present study demonstrates that the HO-1/CO pathway inhibits sFlt-1 and sEng release, providing compelling evidence for a protective role of HO-1 in pregnancy, and identifies HO-1 as a novel target for the treatment of preeclampsia.
No takes yet. Share an insight, caveat, or question.
Cudmore et al. (2007) studied this question. The heme oxygenase-1 (HO-1)/CO pathway inhibits sFlt-1 and sEng release, demonstrating a protective role in pregnancy and identifying HO-1 as a novel therapeutic target for preeclampsia.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: